Xanthelasma
Methodology & AI Transparency ⓘ
Xanthelasma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Eye Health, Glaucoma & Vision Disorders diagnostic criteria (H02.60), workup for Xanthelasma integrates AREDS2 macular nutrition [Xanthelasma H02.60] with evidence-graded therapy tailored to Intraocular Pressure (IOP) [Xanthelasma H02.60] response.
- 2 Real-world patient consensus: Federal ICD-10-CM code H02.60 categorizes Xanthelasma under Eye Health, Glaucoma & Vision Disorders.
- 3 Typical cash cost range: Differential triage of Xanthelasma (H02.60) utilizes AREDS2 macular nutrition [Xanthelasma H02.60].
- 4 Top reported side effects / signs: Follow-up benchmark in Xanthelasma: maintaining Intraocular Pressure (IOP) [Xanthelasma H02.60] within 10 – 21 mmHg (individualized optic target) (H02.60).
Ask our AI Specialists anything about Xanthelasma
What Is Xanthelasma?
Under Eye Health, Glaucoma & Vision Disorders diagnostic criteria (H02.60), workup for Xanthelasma integrates AREDS2 macular nutrition [Xanthelasma H02.60] with evidence-graded therapy tailored to Intraocular Pressure (IOP) [Xanthelasma H02.60] response.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Xanthelasma (H02.60) features impaired trabecular meshwork in Xanthelasma (H02.60: aqueous humor outflow). therapeutic stabilization in eyes & vision is verified against Best-Corrected Visual Acuity in Xanthelasma (H02.60: & OCT).
Common Symptoms & Clinical Signs
- • Presentation of Xanthelasma (H02.60): gradual blurring, glare/halos in Xanthelasma (H02.60: around nighttime headlights,)
- • Secondary Xanthelasma clinical sign: gritty burning, foreign-body in Xanthelasma (H02.60: sensation, reflex tearing,)
- • Symptom flares in Xanthelasma correlating with Intraocular Pressure (IOP) [Xanthelasma H02.60] deviation outside 10 – 21 mmHg (individualized optic target) (H02.60)
- • Functional eyes & vision impact requiring AREDS2 macular nutrition [Xanthelasma H02.60] evaluation (H02.60)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Xanthelasma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | H02.60 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Eye Health, Glaucoma & Vision Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Intraocular Pressure (IOP) [Xanthelasma H02.60] | 10 – 21 mmHg (individualized optic target) (H02.60) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Best-Corrected Visual Acuity in Xanthelasma (H02.60: & OCT) | Intact retinal nerve fiber & macula (H02.60) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & Systemic in Xanthelasma (H02.60: Blood Pressure) | Microvascular retinal protection (H02.60) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Xanthelasma
Treatment selection for Xanthelasma depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Xanthelasma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on RELATIONSHIP BETWEEN OPTICAL COHERENCE TOMOGRAPHY BIOMARKERS AND NUMBER OF: What a 236-Participant Study Found A greater subretinal fluid thickness at baseline was associated with a higher frequency of pro re nata injections over 12 and 24 months in eyes treated with ranibizumab for neovascular age-related macular degeneration. Retina (Philadelphia, Pa.) • 2024-10-01 • Phase III Randomized Trial | N = 236 | 82/100 | PMID 39287532 ↗ |
Xanthelasma Patient Community & “People Like Me” Threads
Filter Xanthelasma community threads and patient logs by age, biological sex, dosage, and treatment duration.